We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
RBI
226
Raiffeisen Bank International
Austria
$1.37M +$760K +20,982 +117%
AAB
227
ABN AMRO Bank
Netherlands
$1.36M +$156K +4,306 +13%
II
228
Inspire Investing
Idaho
$1.36M +$224K +6,195 +19%
Public Employees Retirement Association of Colorado
229
Public Employees Retirement Association of Colorado
Colorado
$1.35M – – –
EMPI
230
Elo Mutual Pension Insurance
Finland
$1.34M +$502K +13,856 +57%
SCM
231
Sterling Capital Management
North Carolina
$1.3M -$86.7K -2,396 -6%
TAF
232
Tredje AP-fonden
Sweden
$1.3M -$1.43M -39,546 -52%
FAM
233
Formidable Asset Management
Ohio
$1.29M +$27.9K +772 +2%
STA
234
Summit Trail Advisors
New York
$1.26M +$1.03M +28,463 +390%
HWM
235
Hohimer Wealth Management
Washington
$1.26M +$124K +3,434 +11%
AIM
236
Aigen Investment Management
New York
$1.25M +$1.28M +35,411 New
KeyBank National Association
237
KeyBank National Association
Ohio
$1.24M +$75K +2,073 +6%
Baird Financial Group
238
Baird Financial Group
Wisconsin
$1.23M -$178K -4,926 -12%
GAM
239
Generali Asset Management
Italy
$1.2M +$1.22M +33,647 +7,753%
Janus Henderson Group
240
Janus Henderson Group
United Kingdom
$1.18M – – –
Daiwa Securities Group
241
Daiwa Securities Group
Japan
$1.17M +$43.2K +1,192 +4%
ET
242
Entropy Technologies
New York
$1.15M -$821K -22,679 -41%
KOC
243
Koss-Olinger Consulting
Florida
$1.13M -$1.27K -35 -0.1%
TI
244
Tidal Investments
Wisconsin
$1.1M -$977 -27 -0.1%
MFS
245
Monetta Financial Services
Illinois
$1.06M – – –
CIBC Asset Management
246
CIBC Asset Management
Ontario, Canada
$1.04M +$4.38K +121 +0.4%
Hudson Bay Capital Management
247
Hudson Bay Capital Management
Connecticut
$1.04M +$10.5K +289 +1%
FF
248
Friedenthal Financial
New Jersey
$1.03M +$1.06M +29,322 New
LCM
249
Landscape Capital Management
New Jersey
$1.01M +$699K +19,296 +208%
PP
250
PDT Partners
New York
$982K -$1.51M -41,693 -60%
8 9
10
11 12

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.